Ophthalmology

Trending topics and milestone stories from 2024 on Ophthalmology Times Europe

Let’s look back on some of the top stories on Modern Retina from 2024 as we gear up for an incredible 2025.

Did you miss any of our print issues this year? Don’t worry, they are still available online.

A study investigating the impact of socioeconomic status on open globe injury (OGI) found that lower SES, measured by the Social Vulnerability Index and Distressed Communities Index, correlates with younger age, non-accidental injuries, and poorer visual outcomes in OGI patients.

Nona Biosciences has partnered with Kodiak Sciences to develop multi-target antibodies for ophthalmic diseases. Utilizing Nona's Harbour Mice platform, the collaboration aims to accelerate antibody discovery, focusing on innovative therapies for retinal and other eye conditions.

Recognition may translate into policy changes and behavioral improvement.

Researchers described the presence of multiple bilateral serous retinal detachments (SRDs) found in 3 women after they used hair dyes.

It is noteworthy that patients with mild TBI often report visual issues despite normal results of visual acuity measurements and fundus examinations.

Nerve cells in the retina were analyzed at the Vienna University of Technology using microelectrodes. According to researchers, the nerve cells demonstrated surprisingly stable behavior, which is good news for retina implants.

This service will provide researchers with tailored animal models that closely mimic human ocular conditions.

The presentation and the moderated Q&A is scheduled for Tuesday, December 3, 2024 in Presentation Room 3 at 1:30 pm ET.

A study found that a simplified artificial circuit, modeled after the brain's neuronal system, can predict network activity and provide insights into how the brain manages short-term memory, with potential implications for novel treatments of eye movement disorders.

Research needed to establish best diagnostic and management strategies for increasingly common condition.

The new PDUFA goal date for NT-501 as treatment for macular telangiectasia type 2 (MacTel) is March 18, 2025.

Harrow has announced an initiative to expand access and affordability for its ophthalmic pharmaceutical products.

Ian C. Han, MD, shares his thoughts on the value of anecdotal evidence in our winter 2024 editorial.

The Healthcare Private Equity team has advised Retina Consultants of America (RCA) and Webster Equity Partners in the sale of RCA to Cencora.

The meeting is set to take place from November 8 to 10, 2024 at the Sheraton Times Square Hotel in New York City.

The candidate, FLQ-101, is a once-daily oral/intravenous solution.

Alfredo Sadun, MD, PhD, is the chief of Ophthalmology at the Doheny Eye Institute of UCLA. At this year's AAO meeting held in Chicago, Illinois, he stopped by the Eye Care Network booth to share insights from the symposium "Professional Longevity 2.0: Assessing the Ophthalmologist," which he presented during.